VuuAI and Amiculum partner to transform content engagement in pharma

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of VuuAI’s novel technology, which is positioned to transform the pharma commercialization model.

VuuAI brings a novel GenAI platform that allows the rapid validation of compliance and pharma brand integrity, plus optimization, transformation, and creation of brand and disease area content. The platform is backed by an industry team with significant experience spanning content, technology, medical, and commercial operations, and enterprise-level workflow transformation. In the future, users of VuuAI are expected to be able to generate dynamic, personalized, and approved marketing and medical content instantaneously, in any format, for delivery via any channel.

The companies will collaborate to partner with pharma and medtech clients in deploying and scaling the platform, aligning VuuAI’s platform with Amiculum’s broader commercial, medical, data security, project, and change management capabilities, to ensure optimal results with maximum efficiency for clients.

Amiculum has made a strategic financial investment in VuuAI, as part of an open seed funding round, and will also be contributing pharmaceutical marketing and medical communications expertise as the product is further developed.

Launch of the first product is expected in early 2026, with engagement already underway with several customers under terms that enable early access, input into features, and significant licensing incentives. Companies using VuuAI will benefit from massive efficiencies in production while also enabling more effective, personalized, and relevant content, driving better results for brands, HCPs, and patients.

Commenting on the agreement, Dr Jenny Putin, Amiculum Co-founder, said: ‘This is a very exciting development for Amiculum and supports our ambition to be a leading technology-enabled independent global healthcare communications agency within the pharmaceutical industry.’

Dr Paul Tunnah, VuuAI CEO and Co-founder, stated: ‘ VuuAI has the potential to completely reimagine the future engagement model of pharmaceutical companies and their agencies. We are delighted to be partnering with Amiculum. Our collaboration will help our clients to see immediate benefit from the technology, while also supporting further development.’